CJC-1295 No DAC & Ipamorelin Research Documentation Best Practices

Solid documentation for these two compounds comes down to four linked records: a batch-specific certificate of analysis, a receiving record that ties that batch to a physical vial in your inventory, a storage and handling log, and research-use-only designation carried consistently across labels, invoices and internal references. The reason this particular pair gets singled out is practical — they are frequently stocked side by side in growth-hormone secretagogue research, and lot-level traceability is the first thing to break when two similar vials share a shelf. Real Peptides supplies both as research-use-only compounds with publicly verifiable COAs, which is what makes the first link in that chain auditable rather than assumed. Nothing here is dosing, preparation, or legal advice.

Why these two compounds end up in the same file

CJC-1295 without DAC is a synthetic growth-hormone-releasing hormone analog; the "no DAC" designation indicates it is supplied without the drug affinity complex used in the longer-acting modified version. Ipamorelin is a selective pentapeptide studied as a ghrelin-receptor agonist. Research literature on growth-hormone secretagogue pathways has examined both classes, and studies indicate the two act through distinct receptor mechanisms — which is precisely why research inventories and wholesale catalogs tend to carry them adjacent to one another, and why buyers building a first order often add both at once.

That proximity is where documentation gets sloppy. Two lyophilized powders of similar appearance, in similar vial formats, arriving in the same shipment on the same invoice, stored in the same unit. If your records treat them as one line item — "GH research compounds, qty 20" — you have no way to reconstruct which lot went where six months later. Every best practice below exists to prevent exactly that collapse.

A second reason to keep the file tight: these are the compounds a downstream buyer, an auditor, or your own counsel is most likely to ask about, because they are widely discussed and widely counterfeited. A clean, lot-level paper trail is the cheapest defense a reseller or clinic-side buyer has.

The records that make a research file defensible

Most buyers already keep some of these. The gap is usually that they live in different systems and nothing ties them to a lot number. Build the file so any single vial can be traced back to a published analysis and forward to its current location.

The register and the COA are the two that matter most to an outside reader. One proves the material was characterized; the other proves you know which characterized material you are holding. Keep both retrievable by lot number rather than by order date — orders get consolidated, lots do not.

How to read a certificate of analysis so it actually proves something

A COA is only evidence if it corresponds to the vial in your hand. Four checks separate a real document from decorative PDF.

Does the lot number on the certificate match the lot on the label? A "representative" COA for a previous batch tells you nothing about the material you received. If a supplier can only produce a generic certificate, treat the batch as uncharacterized.

Is the analytical method stated? Purity claims should name the method — high-performance liquid chromatography is the standard for peptide purity, with mass spectrometry used for identity confirmation. A purity figure with no method attached is a number, not a result.

What else was tested besides purity? Purity by HPLC answers one question: how much of the peptide content is the target sequence. It does not speak to identity confirmation, residual content, or contaminant screening. Real Peptides runs 7-panel batch testing and publishes the panel set alongside each batch — read what the panels actually cover rather than assuming a single purity percentage covers everything.

Can you verify it independently? This is the sharpest dividing line in the wholesale market. Some suppliers email a PDF on request, some charge for COAs as an add-on, and some publish nothing at all and describe their testing in marketing copy. Real Peptides publishes COAs where a prospective buyer can check the lab results themselves before opening an account — which means verification does not depend on a sales conversation.

Keeping lots straight when two compounds share a shelf

Once the COA is verified, the discipline shifts to your side of the transaction. A few practices carry most of the weight.

Log at the vial level on arrival, not the order level. Record compound, lot, quantity received, and the condition of the shipment, and have the person who accepted it sign the entry. Store visually similar compounds in physically separate, distinctly labeled positions — same-shelf storage of two white lyophilized powders with similar labels is the single most common source of mix-ups.

Label internally as well as relying on supplier labels. Internal labels should carry compound name, lot, nominal mass as stated by the supplier, and research-use-only designation. Where material is transferred between storage locations or between projects, log the movement against the lot. Document storage conditions and any excursion — a temperature event you recorded and assessed is a manageable finding; an unrecorded one invalidates everything downstream of it.

One boundary matters more than any of the above. Real Peptides does not provide dosing, administration, titration, or preparation guidance for any catalog compound, because these are research-use-only materials and not FDA-approved drugs for human use. What your records can legitimately capture is what the supplier documents: the nominal mass stated on the label, the lot, and the published analysis. The concentration framework a laboratory works in — mass per unit volume — is the researcher's own calculation and belongs in the researcher's own records. Anything past that point is outside what a wholesale supplier should ever hand a buyer, and outside the scope of this article.

Questions to put to any supplier before you open an account

Documentation quality is a supplier-selection criterion, not a post-purchase problem. Ask these before the first order, and ask them in writing.

Are COAs batch-specific and published, or emailed on request? Is there any charge attached to receiving them? Who performs the testing, and is the analysis in-house, third-party, or a mix? What happens if a batch does not meet specification — is there a documented process, and does the buyer hear about it? How is the wholesale pricing structure presented: are tiers, minimums and terms published, or only disclosed after a sales call? Where does fulfillment originate, and what does the supplier state about turnaround?

Hidden pricing is the pattern worth naming. A program that will not state its tier structure until you have surrendered contact details is optimizing for the sales conversation, not the buyer's evaluation. The same logic applies to testing: if a supplier's quality story cannot be checked without talking to a representative, it is a claim rather than a record. You are entitled to evaluate both on paper.

One more question, often skipped: what is the supplier's own documentation retention practice? If a lot you purchased in 2026 is questioned later, you want the published analysis still to exist.

Compliance and labeling questions that belong with your counsel

This section is informational and is not legal advice. Research-use-only compounds sit in a regulatory area where the relevant questions are jurisdiction-specific and change, so the honest guidance is about what to ask rather than what the answer is.

Bring these to your attorney and, where applicable, your state board: how should research-use-only material be labeled and described in your own catalog, invoices and marketing; what constitutes resale versus distribution under the rules that apply to your business type and license category; what recordkeeping obligations attach to your particular entity; and what representations you may not make in customer-facing copy. If your business is licensed, ask specifically how your board views holding or transferring non-approved research materials — practice varies, and generalizations are not a substitute for a direct answer about your license.

What you should not do is accept a supplier's regulatory summary as your compliance position, yours or anyone's. A supplier can document what the material is and how it was tested. Only your counsel can tell you what your business is permitted to do with it.

What Real Peptides does differently

Real Peptides operates a Wholesale Partner Program built for business buyers — med spas, clinics, telehealth operators and resellers stocking research compounds. The documentation side is specific and checkable: compounds are supplied at 99%+ HPLC purity, every batch goes through 7-panel testing, and the resulting COAs are publicly verifiable rather than gated behind a sales call or sold as an extra. A prospective partner can read the lab results before applying.

Pricing tiers and program terms are presented rather than withheld, so a buyer can evaluate the economics without a discovery call. Fulfillment is US-based, with orders shipping in 5–7 days. Applying runs through a 3-step wholesale application, which keeps qualification straightforward instead of turning it into a procurement project. Across the catalog, compounds are described in research terms only — never as therapeutics, never with preparation or administration guidance — which is the same standard your own documentation should hold to.

If you are stocking growth-hormone secretagogue research compounds and want every lot backed by a published, batch-specific analysis, the Wholesale Partner Program application is the next step; qualified buyers can review pricing and testing documentation as part of that process.

For compound-level details, the CJC-1295 No DAC 10mg and Ipamorelin 10mg pages carry current batch documentation, and related research categories are grouped under Growth Factor & Tissue Signaling Research and the broader Popular Peptides collection.